Multiple Insiders Have Bought Regis, GNC, and More

Page 1 of 2

While we keep track of insider purchases in general, we are particularly interested in stocks that multiple insiders have been buying in a recent period. This is because stocks bought by a consensus of insiders are particularly likely- though not certain, of course- to outperform the S&P 500 (read our analysis of studies on consensus insider purchases). Since investors cannot buy every stock that insiders have bought, we think that it is a good idea to review these stocks, take a brief look at the company, and then decide whether or not each particular stocks is worthy of further research. According to our database of insider trading filings, here are five consumer and retail stocks that multiple insiders have bought in the last three months:

CITADEL INVESTMENT GROUP

Several company officers bought shares of drug store GNC Holdings Inc (NYSE:GNC) in November at prices close to $33 per share. GNC reported high growth in the third quarter of 2012, with sales rising 16% and earnings up 28%. With a trailing earnings multiple of 16, double-digit growth rates would generally be very strong results for a value investor. We would, however, note that the most recent data shows 16% of the outstanding shares of the company held short. Billionaire Ken Griffin’s Citadel Investment Group increased the size of its position in GNC during the third quarter and closed September with 3.5 million shares in its portfolio (see Griffin’s stock picks).

Regis Corporation (NYSE:RGS), an owner and operator of hair salons such as Supercuts with a market capitalization of just under $1 billion, has also had multiple insiders buy share in the past three months. Regis is one of activist fund Starboard Value’s five largest single-stock positions according to its most recent 13F, at 2,8 million shares; Starboard is managed by Jeffrey Smith (find more of Smith’s favorite stocks). Regis is another popular short target, with 21% of the outstanding shares held by short sellers. The forward P/E multiple, based on expected results for the fiscal year ending June 2014, is 21.

Three more consumer stocks insiders love:

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!